Net Product Sales

EYLEA^® net product sales in the United States totaled $363.1 million and $244.4 million for the three months ended September 30, 2013 and 2012, respectively, and $1,006.8 million and $561.9 million for the nine months ended September 30, 2013 and 2012, respectively. In November 2011, the Company received marketing approval from the U.S. Food and Drug Administration ("FDA") for EYLEA (aflibercept) Injection for the treatment of neovascular age-related macular degeneration ("wet AMD"). In September 2012, the Company received marketing approval from the FDA for EYLEA for the treatment of macular edema following central retinal vein occlusion ("CRVO"). In addition, ARCALYST^® net product sales totaled $4.0 million and $4.8 million for the three months ended September 30, 2013 and 2012, respectively, and $12.9 million and $14.7 million for the nine months ended September 30, 2013 and 2012, respectively.

The Company recorded 75% and 79% for the three months ended September 30, 2013 and 2012, respectively, and 76% and 79% for the nine months ended September 30, 2013 and 2012, respectively, of its total gross product revenue from sales to Besse Medical, a subsidiary of AmerisourceBergen Corporation.

Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs (including Medicaid), distribution-related fees, prompt pay discounts, product returns, and other sales-related deductions. The following table summarizes the provisions, and credits/payments, for these sales-related deductions during the nine months ended September 30, 2013.



	Rebates & Chargebacks			Distribution- Related Fees			Other Sales- Related Deductions			Total
Balance as of December 31, 2012	$	2,983		$	15,298		$	545		$	18,826
Provision related to current period sales	18,216			46,428			882			65,526
Credits/payments	(17,166		)	(41,532		)	(894		)	(59,592		)
Balance as of September 30, 2013	$	4,033		$	20,194		$	533		$	24,760